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Serbia and Montenegro is the most recent country
to have joined the European integration processes in
the Western Balkan region. War has troubled this
country for more than ten recent years. Post-war
conditions have been as severe as those during the war
and include poverty and a lack of new, highly
sophisticated technologies and trained professionals
as well as appropriate organisation of the health
services. 
Knowledge of the molecular basis of hereditary
disorders has greatly expanded during the last ten years
and the principle of genetic testing has been introduced
into the clinical practice of  Western countries. In these
countries, with the USA being among the first, genetic
testing for known germline mutations associated with
high lifetime cancer risk, for example those involved in
familial adenomatous polyposis, introduced the use of
consensus data into medical practice. Simultaneously,
inventories (maps) of hereditary disorders with frequency
and spectra of gene mutations causing particular
hereditary diseases were constructed in the majority of
European countries. The delay in transition and
European integration of our country has reflected also
on the status of the investigation of hereditary disorders,
including hereditary breast and ovarian cancer
(HBOC), resulting in the fact that our country is
currently without such a national inventory of its
hereditary disorders.
Breast cancer is one of the most common cancers
diagnosed in women worldwide and a leading cause
of female cancer-related death, despite improvements
made in the field of risk factor definition, early
detection, diagnostics and treatment of the disease. In
central and south-eastern European countries,
incidence and mortality trends also show an increment,
due to recent changes in risk factors (smoking, age at
menarche, age at first pregnancy, oestrogen intake,
etc.). In Serbia and Montenegro, breast cancer is the
most frequent malignancy and the leading cause of
cancer-related death in females as well, with a reported
mortality rate of 16.9 (ASRw) in the year 2000 [1].
Approximately 3,900 new cases of breast cancer are
detected in Serbia and Montenegro each year. Twelve
hundred of these cases are newly diagnosed at the
Institute of Oncology and Radiology of Serbia. 
A subset of breast cancer patients with striking family
histories is suggestive of Mendelian inheritance of
breast cancer risk factors and represents hereditary
breast cancer (HBC). About 5 to 10% of all breast
cancers are considered to be hereditary. The most
common variant of HBC is hereditary breast and
ovarian (HBOC) syndrome. BReast CAncer genes 1
and 2 (BRCA1/2 genes) with incomplete penetrance
have been implicated in about 50% of all hereditary
breast cancers. Discovery of these genes made testing
for genetic predisposition for this disorder possible.
Historically, investigations of BRCA genes in Serbia
and Montenegro started at the end of the nineties in a
collaboration of the Institute for Oncology and
Radiology of Serbia with the National Institute of
Oncology of Hungary in Budapest [2]. Between the
years 2000 to 2003 and 2004 to 2006 joint research
programmes with the Greek National Centre for
Scientific Research “Demokritos” were developed [3].
Both of these collaborations, especially the one with
Greek colleagues, which included the possibility of
more than one working visit, strengthened orientation
toward BRCA testing at the Institute for Oncology and
Radiology of Serbia. In 2004, this institute, with the
financial support of the Ministry of Science of Serbia,
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Table 1. BRCA1 mutations in Serbian breast and/or ovarian families
Family Carcinoma of proband Number of carcinomas 
number (age of onset, year) in family
Breast Ovarian Mutation Exon
4 Breast (31,46) 4 0 5382insC 20
6 Ovarian (22) 1 1 3447del4 11
7 Breast (42) 3 0 5382insC 20
14 Ovarian (69) 0 2 185delAG 2
29 Breast (44) 1 0 C61G 5
purchased a refurbished ABI PRISM 310 genetic
analyser, which enabled complete BRCA testing. 
Firstly, it was necessary to set the conditions for
blood and tissue samples, as well as DNA storage. As
we have already been equipped with liquid nitrogen
containers, tissue and cell samples, as well as DNA
samples for long maintenance, are stored in liquid
nitrogen at minus 196oC. Secondly, in addition to
storage conditions, the most important step towards
BRCA testing is the establishment of a Registry of
Hereditary Breast/Ovarian Cancer. In the Laboratory
of Molecular Genetics, this Registry is presently under
construction, mainly based on medical records from
the Institute for Oncology and Radiology of Serbia. A
genomic DNA bank, consisting of about 190 blood
samples from individuals at risk for hereditary breast
and/or ovarian cancer, has been constructed. Blood
and data of the individuals are included based on
established selection criteria [4]. A formal informed
consent procedure, approved by the Ethics Committee
of the Institute, was initiated in 2004 as part of this
process of inclusion. Approximately 90% of included
individuals are breast/ovarian cancer patients. 
The majority of families included in our bank are
represented by one family member only. Generally,
relatives of breast/ovarian cancer patients refuse to be
tested – in part because of insufficient awareness of
genetic testing and in part because of lack of
appropriate procedures for risk reduction (only invasive
prevention strategies such as prophylactic surgery
demonstrate relevant results in risk reduction). We are
also faced with the problem that our people are
generally suspicious of new health interventions,
especially when they concern genetics. Because of that,
during the last year, we have tried to educate our
primary care physicians through a series of lectures on
hereditary cancer syndromes. A similar educational
programme is being developed for lay persons. 
So far, complete sequencing of the BRCA1 coding
region has been performed in 44 samples. Five
mutations were detected in the examined group (Figure
1). The presence of 4 known mutations, previously
detected elsewhere, has been shown: 185delAG,
3447del4, 5382insC (detected twice) and C61G. The
frequency of mutations was 11%, indicating that the
examined group was predominantly composed of one
or two case families.  
Our preliminary investigation found BRCA 1
mutations in 5 families: three in site-specific breast
cancer families, one in a breast/ovarian cancer family
and one in a family with ovarian cancer only. All
identified mutations, except one, were frameshift
mutations. Family and molecular data are summarised
in Table 1.
As in all countries in transition with very limited
resources, the introduction of highly sophisticated and
very expensive laboratory techniques into clinical
practice is always questionable. Due to the lack of hot
spots or recurrent mutations in the majority of
geographical areas, except in countries with
Fig. 1. BRCA1 mutations found in Serbian breast and breast/ovarian
cancer families – preliminary results (n=44). 1 – without BRCA1
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reproductive isolation such as for example Israel and
Iceland, direct sequencing of the entire coding region
of both BRCA genes is strongly recommended for BRCA
analysis. The exception to this rule appears to be
Poland where only 3 recurrent mutations represent 90%
of all BRCA1 mutation carriers [5]. In countries, such
as ours, without identified founder mutations, whole
gene analysis is recommended, which would make
population-based screening expensive. We therefore
have to answer the difficult question of whether in our
country with limited resources it would be wiser to try
to identify our recurrent mutations, even if they are not
as highly recurrent as for example in Israel and Poland,
and to offer testing for these recurring mutations to a
large population, or to offer sequencing of the entire
coding region of the gene, which is more precise and
covers all mutations, to a highly selected population.
For our country, this question cannot yet be easily
answered due to the lack of population-based studies
of hereditary breast and ovarian cancer patients and
missing follow-up data of BRCA mutation carriers. 
Identification of BRCA mutation carriers,
establishment of spectra and frequency of BRCA
mutations, especially in breast cancer patients, together
with long-term follow-up of mutation carriers, should
allow research on the factors affecting penetrance of
BRCA gene mutations. Further, systemic BRCA analysis
will enable introduction of clinical management for
mutation carriers into the clinical practice of Serbia and
Montenegro, resulting in real benefit for this highly
vulnerable part of the population.                              
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